The improved PARP1 trapping activities of veliparib and olaparib by the L777P mutation has been shown to translate into significantly improved efficacy of both the PARPi in BRCA1m cancer cells (Figs. 7L and 8A). This evidence concerns the gene PARP1 and cancer.